tiprankstipranks
Appili Therapeutics Moves Forward with Aditxt Acquisition
PremiumCompany AnnouncementsAppili Therapeutics Moves Forward with Aditxt Acquisition
4M ago
Appili Therapeutics Highlights Progress and Shareholder Support
Premium
Company Announcements
Appili Therapeutics Highlights Progress and Shareholder Support
5M ago
Appili Therapeutics reports Q2 EPS (C$0.01) vs. (C$0.01) last year
Premium
The Fly
Appili Therapeutics reports Q2 EPS (C$0.01) vs. (C$0.01) last year
5M ago
Appili Therapeutics announces FDA alignment on ATI-1801 NDA requirements
PremiumThe FlyAppili Therapeutics announces FDA alignment on ATI-1801 NDA requirements
5M ago
Appili Updates on Tularemia Vaccine Progress
Premium
Company Announcements
Appili Updates on Tularemia Vaccine Progress
5M ago
Appili Therapeutics presents update on ATI-1701 biodefense vaccine candidate
Premium
The Fly
Appili Therapeutics presents update on ATI-1701 biodefense vaccine candidate
5M ago
Appili Therapeutics Modifies Acquisition Deal with Aditxt
PremiumCompany AnnouncementsAppili Therapeutics Modifies Acquisition Deal with Aditxt
7M ago
Appili Therapeutics Announces Q1 Advancements and Deals
Premium
Company Announcements
Appili Therapeutics Announces Q1 Advancements and Deals
8M ago
Appili Therapeutics Modifies Acquisition Timelines
Premium
Company Announcements
Appili Therapeutics Modifies Acquisition Timelines
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100